Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for two active pharmaceutical ingredients, which will be used in their respective injectable formulations [1] Group 1: Product Approvals - The active pharmaceutical ingredient isomeric phenol trimethyl ether has been approved for use in injectable formulations, primarily for treating acute spasmodic pain caused by digestive system and biliary dysfunction, acute spasmodic urethral, bladder, and renal colic, as well as gynecological spasmodic pain [1] - The company has also obtained the production registration certificate for isomeric phenol injection from the National Medical Products Administration [1] - The active pharmaceutical ingredient dopamine hydrochloride has been approved for use in injectable formulations, mainly for heart failure caused by decreased myocardial contractility in organic heart disease, including low cardiac output syndrome after cardiac surgery [1]
石四药集团(02005.HK)：间苯三酚三甲醚及盐酸多巴酚丁胺获国家药监局批准登记成为在上市制剂使用的原料药